Combining Tanvex’s biosimilar development expertise and U.S. FDA-licensed commercial-scale facility in San Diego, California, with Bora’s extensive global CDMO capabilities, the alliance aims to provide comprehensive solutions to biologics CDMO customers around the world.

FDA Approval of Nypozi™ and FDA BLA Acceptance of TX-05 Further Validates Tanvex's Expertise in Biologics Development and Manufacturing.